Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection against Myocardial Ischemia/ Reperfusion Injury

Zheqing Cai, Gregg L. Semenza

Research output: Contribution to journalArticle


Background-Parenteral administration of recombinant human erythropoietin (rhEPO) to rats induces protection against myocardial ischemia/reperfusion injury 24 hours later. However, the mechanisms by which rhEPO mediates protection have not been determined. Methods and Results-rhEPO was perfused into isolated rat hearts over 15 minutes immediately before 30 minutes of no-flow ischemia and 45 minutes of reperfusion. Compared with saline-perfused control hearts, recovery of left ventricular developed pressure was increased in rhEPO-perfused hearts. rhEPO also increased AKT activity and decreased apoptosis. All of these effects were blocked when the phosphatidylinositol-3-kinase inhibitor wormannin was infused with rhEPO. Conclusions-rhEPO provides immediate protection against ischemia/reperfusion injury in the isolated perfused rat heart that is mediated by the phosphatidylinositol-3-kinase pathway.

Original languageEnglish (US)
Pages (from-to)2050-2053
Number of pages4
Issue number17
StatePublished - May 4 2004



  • Erythropoietin
  • Ischemia
  • Myocardial infarction
  • Reperfusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this